Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide AloneGlobeNewsWire • 05/28/25
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next LevelAccesswire • 05/08/25
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program ProgressGlobeNewsWire • 05/08/25
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation ConferenceGlobeNewsWire • 03/31/25
Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a TurnaroundZacks Investment Research • 03/06/25
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program ProgressGlobeNewsWire • 02/13/25
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight ReductionGlobeNewsWire • 01/27/25
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting DisordersGlobeNewsWire • 11/26/24
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeekGlobeNewsWire • 11/05/24